Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | MITF | O75030 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23099307 | 0.90 | KDM4E (0.46) | ALDH1A1KMT2AL3MBTL1MEN1ADRA2C | |
| SCHEMBL18666146 | 0.89 | ADRA2C (0.54) | ALDH1A1KMT2AL3MBTL1MEN1POLB | |
| SCHEMBL29660113 | 0.89 | ADRA2C (0.54) | ALDH1A1KMT2AL3MBTL1MEN1POLB | |
| SCHEMBL18666199 | 0.89 | DEGS1 (0.49) | ALDH1A1KMT2AL3MBTL1MEN1POLB | |
| SCHEMBL18666149 | 0.88 | ALDH1A1 (0.55) | ALDH1A1KMT2AMEN1POLBLMNA | |
| SCHEMBL18666157 | 0.85 | ALDH1A1 (0.48) | ALDH1A1KMT2AL3MBTL1MEN1POLB | |
| SCHEMBL18666150 | 0.82 | MTNR1B (0.47) | ALDH1A1L3MBTL1ADRA2CKDM4EGAA | |
| SCHEMBL18666151 | 0.82 | MTNR1B (0.63) | ALDH1A1KMT2AMEN1POLBLMNA | |
| SCHEMBL30567101 | 0.82 | MTNR1B (0.63) | ALDH1A1KMT2AMEN1POLBLMNA | |
| SCHEMBL31120716 | 0.79 | MTNR1B (0.47) | ALDH1A1L3MBTL1ADRA2CGAATAOK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11345656-B2 | PCNA inhibitors | CITY OF HOPE (US) | 2022-05-31 | — | — | US | disclosed |
| US-20210078938-A1 | PCNA INHIBITORS | THE GOVERNMENT OF THE UNITED STATES AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2021-03-18 | — | — | US | disclosed |
| US-10913706-B2 | PCNA inhibitors | CITY OF HOPE (US) | 2021-02-09 | — | — | US | disclosed |
| US-20200216386-A1 | PCNA INHIBITORS | UNITED STATES GOVERNMENT | 2020-07-09 | — | — | US | disclosed |
| US-10550070-B2 | PCNA inhibitors | CITY OF HOPE (US) | 2020-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10913706-B2 | PCNA inhibitors | PCNA, MKI67, PCLAF | ALDH1A1 3079/4885KMT2A 1384/4885L3MBTL1 1829/4885 |
| US-20210078938-A1 | PCNA INHIBITORS | PCNA, MKI67, PCLAF | ALDH1A1 3079/4885KMT2A 1384/4885L3MBTL1 1829/4885 |
| US-11345656-B2 | PCNA inhibitors | PCNA, MKI67, PCLAF | ALDH1A1 3079/4885KMT2A 1384/4885L3MBTL1 1829/4885 |
| US-10550070-B2 | PCNA inhibitors | PCNA, MKI67, PCLAF | ALDH1A1 3079/4885KMT2A 1384/4885L3MBTL1 1829/4885 |
| US-20200216386-A1 | PCNA INHIBITORS | PCNA, MKI67, PCLAF | ALDH1A1 3079/4885KMT2A 1384/4885L3MBTL1 1829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.